HPV Vaccine Cuts Precancerous Lesions Nearly 80% in 20 Years as U.S. Coverage Lags at 60%
Updated
Updated · WBAY · Jun 8
HPV Vaccine Cuts Precancerous Lesions Nearly 80% in 20 Years as U.S. Coverage Lags at 60%
3 articles · Updated · WBAY · Jun 8
Summary
Twenty years after FDA approval on June 8, 2006, the HPV vaccine is credited with sharply reducing HPV-linked disease, including nearly an 80% drop in precancerous cervical lesions since 2008.
The vaccine now targets nine HPV strains—expanded from four in 2014—covering viruses tied to about 90% of HPV-caused cancers worldwide and helping cut cervical, genital, and head-and-neck cancers.
Vaccination still trails public-health goals: just over half of Wisconsin teens ages 13 to 18 have completed the series, and only about 60% of U.S. adolescents are up to date.
Doctors recommend starting at ages 9 to 12, when immune response is stronger and protection begins before exposure risk; the shot is now available through age 45 after clinician-patient discussion.
The gap matters because HPV remains widespread—about 42 million Americans are infected, 13 million new infections occur each year, and the virus is linked to roughly 36,000 U.S. cancer cases annually.
One dose or two? With conflicting HPV vaccine advice, what should parents do now?
A proven vaccine prevents 90% of certain cancers. Why are vaccination rates still so low?
Closing the HPV Vaccination Gap: Barriers, Disparities, and the Path to Cervical Cancer Elimination in the U.S.
Overview
The HPV vaccine is a powerful tool that can prevent several cancers, yet its adoption in the U.S. faces persistent challenges. Although health authorities recommend vaccination for adolescents and have structured schedules to maximize protection, many barriers—such as cost, access, and the need for multiple doses—limit coverage. New research suggests that even a single dose may provide strong protection, which could make vaccination easier and more accessible. Addressing these challenges is crucial to ensure that this highly effective vaccine reaches its full public health potential and protects more communities from HPV-related cancers.